JP7579284B2 - セマフォリン４ｄ遮断（ｓｅｍａ４ｄ）とｄｃ１療法との併用療法 - Google Patents

セマフォリン４ｄ遮断（ｓｅｍａ４ｄ）とｄｃ１療法との併用療法 Download PDF

Info

Publication number
JP7579284B2
JP7579284B2 JP2021576300A JP2021576300A JP7579284B2 JP 7579284 B2 JP7579284 B2 JP 7579284B2 JP 2021576300 A JP2021576300 A JP 2021576300A JP 2021576300 A JP2021576300 A JP 2021576300A JP 7579284 B2 JP7579284 B2 JP 7579284B2
Authority
JP
Japan
Prior art keywords
cancer
her2
sema4d
antibody
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021576300A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022537453A5 (cg-RX-API-DMAC10.html
JP2022537453A (ja
Inventor
ブライアン チェルニエッキ
クリティカ コドゥムディ
エリザベス エヴァンス
Original Assignee
バクシネックス インコーポレーティッド
エイチ リー モフィット キャンサー センター アンド リサーチ インスティテュート インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by バクシネックス インコーポレーティッド, エイチ リー モフィット キャンサー センター アンド リサーチ インスティテュート インコーポレイテッド filed Critical バクシネックス インコーポレーティッド
Publication of JP2022537453A publication Critical patent/JP2022537453A/ja
Publication of JP2022537453A5 publication Critical patent/JP2022537453A5/ja
Application granted granted Critical
Publication of JP7579284B2 publication Critical patent/JP7579284B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4203—Receptors for growth factors
    • A61K40/4205—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/49—Breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
JP2021576300A 2019-06-21 2020-06-19 セマフォリン４ｄ遮断（ｓｅｍａ４ｄ）とｄｃ１療法との併用療法 Active JP7579284B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962865027P 2019-06-21 2019-06-21
US62/865,027 2019-06-21
PCT/US2020/038719 WO2020257640A1 (en) 2019-06-21 2020-06-19 Combination therapy with semaphorin-4d blockade (sema4d) and dc1 therapy

Publications (3)

Publication Number Publication Date
JP2022537453A JP2022537453A (ja) 2022-08-25
JP2022537453A5 JP2022537453A5 (cg-RX-API-DMAC10.html) 2023-05-30
JP7579284B2 true JP7579284B2 (ja) 2024-11-07

Family

ID=71575807

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021576300A Active JP7579284B2 (ja) 2019-06-21 2020-06-19 セマフォリン４ｄ遮断（ｓｅｍａ４ｄ）とｄｃ１療法との併用療法

Country Status (10)

Country Link
US (2) US11660330B2 (cg-RX-API-DMAC10.html)
EP (1) EP3986446B1 (cg-RX-API-DMAC10.html)
JP (1) JP7579284B2 (cg-RX-API-DMAC10.html)
KR (1) KR20220044490A (cg-RX-API-DMAC10.html)
CN (1) CN114364399A (cg-RX-API-DMAC10.html)
AU (1) AU2020297592A1 (cg-RX-API-DMAC10.html)
BR (1) BR112021025795A2 (cg-RX-API-DMAC10.html)
IL (1) IL288779B2 (cg-RX-API-DMAC10.html)
MX (1) MX2021015970A (cg-RX-API-DMAC10.html)
WO (1) WO2020257640A1 (cg-RX-API-DMAC10.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240009232A1 (en) * 2020-08-21 2024-01-11 H. Lee Moffitt Cancer Center And Research Institute, Inc. Combination therapy comprising her-2-dc1 vaccine and a probiotic
US20260232728A1 (en) * 2023-01-26 2026-08-13 H. Lee Moffitt Cancer Center And Research Institute, Inc. Methods for identifying disseminated cancer cells in breast cancer patients
WO2024159105A1 (en) * 2023-01-26 2024-08-02 H. Lee Moffitt Cancer Center And Research Institute, Inc. Methods of treating cancer comprising administration of intratumoral dcs in combination with systemic igg monoclonal antibody

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016528195A (ja) 2013-06-25 2016-09-15 バクシネックス インコーポレーティッド 腫瘍成長および転移を阻害するための免疫調節療法との組み合わせでのセマフォリン−４ｄ阻害分子の使用
JP2018515421A (ja) 2015-05-22 2018-06-14 ブライアン ジェイ ツェルニキＣＺＥＲＮＩＥＣＫＩ， Ｂｒｉａｎ， Ｊ． 複数用量注射準備済樹状細胞ワクチンの製造

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1601438A (cg-RX-API-DMAC10.html) 1968-10-17 1970-08-24
US4342566A (en) 1980-02-22 1982-08-03 Scripps Clinic & Research Foundation Solid phase anti-C3 assay for detection of immune complexes
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
CA2090473A1 (en) 1990-08-29 1992-03-01 Robert M. Kay Homologous recombinatin in mammalian cells
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
FR2686087A1 (fr) 1992-01-13 1993-07-16 Inst Nat Sante Rech Med Nouvel antigene lymphocytaire, anticorps correspondant et leurs applications.
US5652138A (en) 1992-09-30 1997-07-29 The Scripps Research Institute Human neutralizing monoclonal antibodies to human immunodeficiency virus
CA2163032C (en) 1993-06-03 2001-02-06 John Landon Antibody fragments in therapy
US6180377B1 (en) 1993-06-16 2001-01-30 Celltech Therapeutics Limited Humanized antibodies
US6130364A (en) 1995-03-29 2000-10-10 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
US6410690B1 (en) 1995-06-07 2002-06-25 Medarex, Inc. Therapeutic compounds comprised of anti-Fc receptor antibodies
FR2765243B1 (fr) 1997-06-30 1999-07-30 Usinor Acier inoxydable austenoferritique a tres bas nickel et presentant un fort allongement en traction
WO2008100995A1 (en) 2007-02-14 2008-08-21 Vaccinex, Inc. Humanized anti-cd100 antibodies
EP2427212B1 (en) 2009-05-08 2017-08-23 Vaccinex, Inc. Anti-cd100 antibodies and methods for using the same
JP2017512493A (ja) * 2014-03-14 2017-05-25 ブライアン ジェイ ツェルニキＣＺＥＲＮＩＥＣＫＩ， Ｂｒｉａｎ， Ｊ． 癌のｃｄ４＋ｔヘルパー１型応答の監視方法および免疫回復
US10574441B2 (en) * 2014-05-26 2020-02-25 Nokia Technologies Oy Management of cryptographic keys
CA2955445A1 (en) * 2014-07-17 2016-01-21 Brian J. Czerniecki Manufacturing of multi-dose injection ready dendritic cell vaccines and combination therapy for blocking her2 and her3

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016528195A (ja) 2013-06-25 2016-09-15 バクシネックス インコーポレーティッド 腫瘍成長および転移を阻害するための免疫調節療法との組み合わせでのセマフォリン−４ｄ阻害分子の使用
JP2018515421A (ja) 2015-05-22 2018-06-14 ブライアン ジェイ ツェルニキＣＺＥＲＮＩＥＣＫＩ， Ｂｒｉａｎ， Ｊ． 複数用量注射準備済樹状細胞ワクチンの製造

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Cancer Research，2012年，Vol.72, Issue 8, Supplement LB-133
Sci. Transl. Med.，2018年，Vol.10, eaao5931 (14 pages)

Also Published As

Publication number Publication date
US20200397881A1 (en) 2020-12-24
IL288779B1 (en) 2025-07-01
MX2021015970A (es) 2022-04-06
US12201719B2 (en) 2025-01-21
BR112021025795A2 (pt) 2022-02-01
US11660330B2 (en) 2023-05-30
WO2020257640A1 (en) 2020-12-24
CA3142777A1 (en) 2020-12-24
EP3986446A1 (en) 2022-04-27
CN114364399A (zh) 2022-04-15
US20240050544A1 (en) 2024-02-15
IL288779A (en) 2022-02-01
JP2022537453A (ja) 2022-08-25
IL288779B2 (en) 2025-11-01
EP3986446B1 (en) 2026-08-05
AU2020297592A1 (en) 2022-01-06
KR20220044490A (ko) 2022-04-08

Similar Documents

Publication Publication Date Title
JP2023524530A (ja) 免疫原性が低い癌の癌細胞死滅を増強するための３剤併用療法
US12201719B2 (en) Combination therapy with semaphorin-4D blockade (SEMA4D) and DC1 therapy
JP2017537892A (ja) 疾患の処置のための併用療法
JP7473474B2 (ja) 抗体－薬物コンジュゲート投与による転移性脳腫瘍の治療
US20230086099A1 (en) Combination therapy for treatment of cancer and cancer metastasis
US20250122308A1 (en) Targeting mutant kras with a mutation specific iga
EP3773742A1 (en) Cell assembly-mediated delivery of checkpoint inhibitors for cancer immunotherapy
US20210393793A1 (en) Axl-specific antibodies for treatment of non-small cell lung cancer
JP2021517153A5 (ja) Ｍｏｓｐｄ２およびｔ細胞またはｎｋ細胞特異的分子に対する二重特異性抗体
US20220370496A1 (en) Her3 pulsed dc1 therapy
JP2021529762A (ja) 術後治療用ｉｎ ｓｉｔｕ噴霧生体応答性免疫療法ゲル
CA3142777C (en) Combination therapy with semaphorin-4d blockade (sema4d) and dc1 therapy
RU2801828C2 (ru) Комбинированная терапия блокированием семафорина 4d (sema4d) и терапией дк1
US20250376522A1 (en) Targeting Cells with a Combination of CXCR2 Inhibition and CD47 Blockade
WO2024036232A2 (en) Bispecific antibodies and uses thereof
WO2022040341A1 (en) Abscopal therapy for cancer
US20250230260A1 (en) Cdrs for glycosylated acat1
US20260008844A1 (en) Use of anti-marco antibody with a checkpoint blockade antibody for the treatment of cancer
WO2024159105A1 (en) Methods of treating cancer comprising administration of intratumoral dcs in combination with systemic igg monoclonal antibody
WO2024158763A2 (en) Lilrb2 binding molecules and methods of use
JP2025530130A (ja) 抗ｔｍｅｆｆ２×ｃｄ３二重特異性抗体でがんを治療する方法
CA2997130C (en) Antibodies specific to human t-cell immunoglobulin and itim domain (tigit)
EP4622655A1 (en) Bispecific chimeric antigen receptor immune cells
TW202523693A (zh) 手術前後基於抗ｐｄ－１之治療
TW202511292A (zh) 用於治療ＮＳＣＬＣ及ｃＨＬ之ＰＤ－１／ＴＩＭ－３結合蛋白

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20211220

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230522

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230522

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20230728

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240502

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240709

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20241001

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20241025

R150 Certificate of patent or registration of utility model

Ref document number: 7579284

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150